Taking PBMs To The “OR”: Orphan Reinsurance Model Could Be New “Middleman” Role
MIT Center for Biomedical Innovation is proposing creation of Orphan Reinsurance Benefit Managers as one mechanism to help finance curative cellular and gene therapies. The idea may or may not prove viable – but it is a reminder that “middlemen” aren’t likely going away even if rebates do.
You may also be interested in...
First-ever implementation of often-discussed reimbursement approach for high-cost drugs would involve group of commercial payers to address “portability” issue and may start with Novartis’ Zolgensma.
Price decisions based on straight calculation of medical costs avoided may overestimate value of a cure, Cassidy warns.
HHS proposal to eliminate the “safe harbor” that allows for prescription drug rebates took a long time to clear White House review. Its release sends a clear message that US HHS Secretary Azar wants to lead the drug pricing debate in 2019.